Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

A prespecified interim analysis of the PATHFINDER study: Performance of a multicancer early detection test in support of clinical implementation.

A cancer signal was detected in 38/4011 (0.95%). Using a conservative minimal PPV that treated all discordant positives as false positives, PPV was 43.3% (13/30, 95% CI 27.4-60.8%). Among 13 detected cancers, top cancer-signal-origin accuracy was 92.3% (12/13). Nine cancer types were represented among those 13 cases.

ASCO Annual Meeting 2021PubMed 37805216